{
  "thread": {
    "uuid": "cd6699d3616fc77b7ec040f5e58267c622193c6b",
    "url": "https://medicaldialogues.in/medicine/news/high-dose-recombinant-vaccine-may-enhance-protection-against-influenza-among-adults-aged-50-64-122217",
    "site_full": "medicaldialogues.in",
    "site": "medicaldialogues.in",
    "site_section": "https://medicaldialogues.in/",
    "site_categories": [
      "media"
    ],
    "section_title": "Medical News, Health News Latest, Medical News Today - Medical Dialogues |",
    "title": "High-Dose Recombinant Vaccine may Enhance Protection Against Influenza among Adults Aged 50-64",
    "title_full": "High-Dose Recombinant Vaccine may Enhance Protection Against Influenza among Adults Aged 50-64",
    "published": "2023-12-29T00:00:00.000+02:00",
    "replies_count": 0,
    "participants_count": 1,
    "site_type": "news",
    "country": "IN",
    "main_image": "https://medicaldialogues.in/h-upload/2020/07/09/131430-influenza.jpg",
    "performance_score": 0,
    "domain_rank": 54547,
    "domain_rank_updated": "2023-12-26T12:06:25.000+02:00",
    "reach": null,
    "social": {
      "facebook": {
        "likes": 0,
        "comments": 0,
        "shares": 0
      },
      "gplus": {
        "shares": 0
      },
      "pinterest": {
        "shares": 0
      },
      "linkedin": {
        "shares": 0
      },
      "stumbledupon": {
        "shares": 0
      },
      "vk": {
        "shares": 0
      }
    }
  },
  "uuid": "cd6699d3616fc77b7ec040f5e58267c622193c6b",
  "url": "https://medicaldialogues.in/medicine/news/high-dose-recombinant-vaccine-may-enhance-protection-against-influenza-among-adults-aged-50-64-122217",
  "ord_in_thread": 0,
  "parent_url": null,
  "author": "Dr.Niharika Harsha B",
  "published": "2023-12-29T00:00:00.000+02:00",
  "title": "High-Dose Recombinant Vaccine may Enhance Protection Against Influenza among Adults Aged 50-64",
  "text": "[Home](/) [Medical news & Guidelines](/medical-news) [Anesthesiology](/anesthesia) [Cardiology and CTVS](/cardiology-ctvs) [Critical Care](/critical-care) [Dentistry](/dentistry) [Dermatology](/dermatology) [Diabetes and Endocrinology](/diabetes-endocrinology) [ENT](/ent) [Gastroenterology](/gastroenterology) [Medicine](/medicine) [Nephrology](/nephrology) [Neurology](/neurology-neurosurgery) [Obstretics-Gynaecology](/obstetrics-gynaecology) [Oncology](/oncology) [Ophthalmology](/ophthalmology) [Orthopaedics](/orthopaedics) [Pediatrics-Neonatology](/pediatrics-neonatology) [Psychiatry](/psychiatry) [Pulmonology](/pulmonology) [Radiology](/radiology) [Surgery](/surgery) [Urology](/urology) [Laboratory Medicine](/laboratory-medicine) [Diet](/diet-nutrition) [Nursing](/nursing) [Paramedical](/paramedical) [Physiotherapy](/physiotherapy) [Health news](/news/health) [AYUSH](/ayush) [State News](/state-news) [Andaman and Nicobar Islands](/state-news/andaman-and-nicobar-islands) [Andhra Pradesh](/state-news/andhra-pradesh) [Arunachal Pradesh](/state-news/arunachal-pradesh) [Assam](/state-news/assam) [Bihar](/state-news/bihar) [Chandigarh](/state-news/chandigarh) [Chattisgarh](/state-news/chattisgarh) [Dadra and Nagar Haveli](/dadra-and-nagar-haveli) [Daman and Diu](/state-news/daman-and-diu) [Delhi](/state-news/delhi) [Goa](/state-news/goa) [Gujarat](/state-news/gujarat) [Haryana](/state-news/haryana) [Himachal Pradesh](/state-news/himachal-pradesh) [Jammu & Kashmir](/state-news/jammu-kashmir) [Jharkhand](/state-news/jharkhand) [Karnataka](/state-news/karnataka) [Kerala](/state-news/kerala) [Ladakh](/state-news/ladakh) [Lakshadweep](/state-news/lakshadweep) [Madhya Pradesh](/state-news/madhya-pradesh) [Maharashtra](/state-news/maharashtra) [Manipur](/state-news/manipur) [Meghalaya](/state-news/meghalaya) [Mizoram](/state-news/mizoram) [Nagaland](/state-news/nagaland) [Odisha](/state-news/odisha) [Puducherry](/state-news/puducherry) [Punjab](/state-news/punjab) [Rajasthan](/state-news/rajasthan) [Sikkim](/state-news/sikkim) [Tamil Nadu](/state-news/tamil-nadu) [Telangana](/state-news/telangana) [Tripura](/state-news/tripura) [Uttar Pradesh](/state-news/uttar-pradesh) [Uttrakhand](/state-news/uttrakhand) [West Bengal](/state-news/west-bengal) [Medical Education](/news/education) [Industry](/news/industry) High-Dose Recombinant Vaccine may Enhance Protection Against Influenza among Adults Aged 50-64 In a groundbreaking cluster-randomized observational study, Kaiser Permanente Northern California has unveiled compelling evidence supporting the superiority of a high-dose recombinant influenza vaccine over standard-dose egg-based vaccines. The study concluded that the high-dose recombinant vaccine was more protective than the standard egg-based vaccine. The study was conducted during the 2018–2019 and 2019–2020 influenza seasons and involved a staggering 1,630,328 vaccinees aged 18 to 64 years. The study results were published in The New England Journal of Medicine. This cutting-edge research, driven by the imperative to evaluate the relative effectiveness of vaccine formulations, focused on adults aged 50 to 64 years—the primary target age group. The high-dose recombinant vaccine, known as Flublok Quadrivalent, contained an impressive three times the amount of hemagglutinin protein, a critical component for immune response, compared to conventional egg-based vaccines. Furthermore, the recombinant formulation demonstrated resilience against antigenic drift during manufacturing, a notable advantage in vaccine development. As there is uncertainty on the relative effectiveness of various vaccines, Kaiser Permanente Northern California facilities conducted a cluster-randomized observational study to evaluate the relative effectiveness of recombinant vaccines. The study, employing a cluster-randomized design, saw Kaiser Permanente Northern California facilities alternate weekly between the high-dose recombinant vaccine and two standard-dose influenza vaccines. The primary outcome of interest was laboratory-confirmed influenza (A or B) identified through polymerase chain reaction (PCR) testing. Secondary outcomes encompassed influenza A and B subtypes, as well as influenza-related hospitalization rates. The results, unveiled after a meticulous analysis employing Cox regression, revealed a striking disparity in vaccine effectiveness between the two formulations. Results: - Among participants aged 50 to 64 years, the recombinant vaccine demonstrated a 15.3% higher relative effectiveness against PCR-confirmed influenza compared to standard-dose vaccines. - This translates to a notable reduction in influenza cases, with 559 participants per 1000 testing positive in the recombinant-vaccine group, as opposed to 925 participants per 1000 in the standard-dose group. - Notably, the heightened protection extended to specific influenza subtypes, with the recombinant vaccine exhibiting a 15.7% higher relative effectiveness against influenza A in the same age group. - This robust efficacy against influenza A, a strain known for its severity, underscores the potential public health impact of adopting advanced vaccine formulations. - However, while the high-dose recombinant vaccine emerged as a standout performer in preventing PCR-confirmed influenza, it did not demonstrate a significant advantage in protecting against influenza-related hospitalization when compared to standard-dose vaccines. In conclusion, this comprehensive study underscores the substantial benefits of the high-dose recombinant influenza vaccine for adults aged 50 to 64 years. The threefold increase in hemagglutinin protein content and resistance to antigenic drift position the recombinant formulation as a frontrunner in influenza vaccine development. As the world grapples with evolving health challenges, research of this nature paves the way for enhanced protection against seasonal influenza, offering a glimmer of hope for a healthier and more resilient future. Further reading: Recombinant or Standard-Dose Influenza Vaccine in Adults under 65 Years of Age. N Engl J Med 2023; 389:2245-2255. DOI: [10.1056/NEJMoa2302099](https://www.nejm.org/doi/full/10.1056/NEJMoa2302099?query=TOC&cid=NEJM%20eToc,%20December%2014,%202023%20DM2309546_NEJM_Subscriber&bid=1981731061) BDS, MDS Dr.Niharika Harsha B (BDS,MDS) completed her BDS from Govt Dental College, Hyderabad and MDS from Dr.NTR University of health sciences(Now Kaloji Rao University). She has 4 years of private dental practice and worked for 2 years as Consultant Oral Radiologist at a Dental Imaging Centre in Hyderabad. She worked as Research Assistant and scientific writer in the development of Oral Anti cancer screening device with her seniors. She has a deep intriguing wish in writing highly engaging, captivating and informative medical content for a wider audience. She can be contacted at editorial@medicaldialogues.in.",
  "highlightText": "",
  "highlightTitle": "",
  "highlightThreadTitle": "",
  "language": "english",
  "sentiment": "positive",
  "categories": [
    "Science and Technology",
    "Human Interest",
    "Health"
  ],
  "external_links": [
    "https://www.nejm.org/doi/full/10.1056/NEJMoa2302099?query=TOC&cid=NEJM%20eToc,%20December%2014,%202023%20DM2309546_NEJM_Subscriber&bid=1981731061)",
    "https://www.nejm.org/doi/full/10.1056/NEJMoa2302099",
    "https://nejm.org/doi/full/10.1056/NEJMoa2302099?query=TOC&cid=NEJM%20eToc,%20December%2014,%202023%20DM2309546_NEJM_Subscriber&bid=1981731061)"
  ],
  "external_images": [],
  "entities": {
    "persons": [],
    "organizations": [
      {
        "name": "enhance protection against influenza",
        "sentiment": "neutral"
      },
      {
        "name": "arunachal pradesh",
        "sentiment": "none"
      },
      {
        "name": "state news",
        "sentiment": "none"
      }
    ],
    "locations": [
      {
        "name": "assam",
        "sentiment": "none"
      },
      {
        "name": "andhra pradesh",
        "sentiment": "none"
      },
      {
        "name": "nicobar islands",
        "sentiment": "none"
      }
    ]
  },
  "rating": null,
  "crawled": "2023-12-29T02:35:06.179+02:00",
  "updated": "2023-12-29T02:35:06.179+02:00"
}